President, Chief Executive Officer
Tony J. Hunt was named our President and Chief Executive Officer and has served on our Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to our Board of Directors his deep understanding of the bioprocessing market.
Chief Financial Officer
Jon K. Snodgres joined Repligen in July 2014 as our Chief Financial Officer, where he oversees financial operations for the Company. Mr. Snodgres was previously with Maquet Cardiovascular, a medical device company, where he served as CFO for five years. At Maquet, in addition to being responsible for the preparation and oversight of the company’s financial statements, he was a key participant in growth planning and profit improvement strategies. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific in various roles, most recently as Vice President of Finance for the Laboratory Products Group. He began his career in finance at AlliedSignal/Honeywell International. Mr. Snodgres received a B.S. in Business Administration, Finance from Northern Arizona University.
Senior Vice President, Research and Development
Ralf Kuriyel joined Repligen in October 2016 as our Senior Vice President, Research and Development where he oversees the Company’s research and development efforts. Mr. Kuriyel was previously Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation, whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. Mr. Kuriyel received a B.S. and M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed his coursework for the Tufts University Ph.D. program in chemical Engineering. He is an inventor of multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.
Senior Vice President, Operations and Information Technology
Jim Bylund joined Repligen in March of 2020 as Senior Vice President, Global Operations and IT. Prior to joining Repligen, Jim spent ten years at Thermo Fisher Scientific in a number of roles including Vice President and General Manager of the Single Use Technologies Business Unit and Vice President of Global Operations for the Bioproduction Division. Prior to joining Thermo Fisher, Jim also worked for Fiserv (9 years) and Eli Lilly and Company (7 years) in a variety of leadership roles. Jim has significant experience in managing multiple operating sites across the globe and scaling operations to meet rapidly growing demand. Jim is a passionate proponent of continuous improvement and has consistently demonstrated the ability to assemble and grow highly effective teams. He received a B.S in Accounting from Utah State University and a Masters Degree in Business Administration from Indiana University.
Vice President, Systems and Automation
Gautam Choudhary joined Repligen in November 2018 as Vice President and General Manager of Bioprocess Systems and Automation. He is responsible for building the infrastructure and developing the strategy for TFF systems and advancing workflows for continuous manufacturing. Before coming to Repligen, Gautam worked at Lonza supporting strategic and operational projects and developing the go-to-market strategy for Cell and Gene Therapy for Bioscience Solutions. Prior to Lonza, he spent twelve years at Life Technologies/Thermo Fisher leading the Cell Culture (Gibco) business for Bioproduction. Before joining Life, he held several technical and commercial roles at Millipore in Asia and Europe supporting filtration, chromatography and the systems business. Mr. Choudhary holds a Bachelor's Degree in Mechanical Engineering and an MBA in Marketing from Leeds University, UK.
Vice President, Global Operations
Before joining Repligen in 2015, Steve Curran was a Global Network Leader of Life Technologies/Thermo Fisher Scientific. For the last 10 years, Mr. Curran has managed Global Genetic Analysis and Chromatography consumables operations at multiple sites around the globe, building efficient operations utilizing Lean methodologies and upgrading Quality systems. He also led the design, construction and commissions of two multiple-product plants that meet stringent regulatory requirements. Prior to this role, Mr. Curran worked as a Development Engineer for 15 years in the biotechnology industry at different levels of leadership, with roles including product transfer, process scale-up and validation. He received a B.S. in Chemical Engineering from WPI in Worcester, MA.
Global Head, Human Resources
Ken Elmer joined Repligen in November 2016. He has over 30 years of experience in the professional services industry, IT services and technical and management consulting. Ken has worked with high growth and entrepreneurial companies in multiple countries and in a wide variety of industries, including Manufacturing, Insurance. Financial Services, Life Sciences, Distribution and Telecommunications. Most recently, Ken was the Chief Human Resources Officer of Attune Consulting, a global SAP service provider. Prior to that, he was with Celerant Consulting, an Operations Management consulting firm, as the Senior Vice President of Human Resources. Other previous leadership positions include Vice President of Human Resources at GlassHouse Technologies, Chief People Officer at Viant Corporation and Vice President of HR at Cambridge Technology Partners, where he held numerous line and leadership roles over nine years, including launching operations in both Ireland and Switzerland.
Senior Vice President, Filtration and Chromatography
Before joining Repligen in 2015, Christine Gebski was Head of the POROS® Business Unit within the Bioproduction Division of Applied Biosystems/LIFE Technologies/Thermo Fisher Scientific, working with purification products, including POROS® and CaptureSelect® chromatography resins. She managed Global Process Chromatography Applications for ten years, developing collateral and providing technical support, supporting new product development and manufacturing process improvement efforts. She also managed R&D, developing and commercializing three new chromatography resins. Before joining LIFE Technologies, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry, with roles in both development and engineering functions, including developing, scaling, transferring and validating downstream purification processes. She received a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.
Vice President, Marketing
Rachel Goodrich was named Vice President of Marketing in March 2017 after joining Repligen in January 2015. She rebranded Repligen as a bioprocessing company, developed and launched the Repligen website, implemented high ROI tools from online Marketing-On-Demand to global technical roadshows, building out an organization covering strategic marketing, digital marketing, creative design and marketing communications. Prior to joining Repligen, she was Market Development Leader for the Bioproduction Division of LIFE Technologies/ Thermo Fisher Scientific/ Applied Biosystems, responsible for global market development and marketing programs for four franchise business units, and was the recipient of numerous Marketing Excellence Awards. She holds a Bachelor's degree in Economics from the University of the Philippines, a Master's Degree in Economics, a Master's Degree in Education and completed all course work for a Ph.D. in Economics from Stanford University.
Vice President, Chromatography
Vikas Gupta joined Repligen in March 2016 as Vice President of Business Development and Strategy. Prior to joining Repligen, Mr. Gupta worked at GE Life Sciences from 2012 to 2015 in commercial leadership roles managing its Enterprise Solutions & Services business as well as the single-use and filtration portfolio. Before GE, Mr. Gupta worked at Millipore from 2004 to 2011 in business development and product management roles, playing an instrumental role in the early growth of its Mobius single-use bioprocessing business. He is one of the early champions of a risk-based approach in assessing the impact of extractables and leachables, as well as sustainability initiatives for the disposal of disposables. He received his B.S. in Chemical engineering and an MBA from India, and an M.S. in Finance from Bentley University in Waltham, MA.
Senior Vice President, Analytics
Before joining Repligen in 2019, Craig Harrison served as the President and Founder of C Technologies, Inc. for over 35 years. Craig and his team worked closely with a wide range of industries to deliver fiber optic assemblies, instrumentation, and systems for spectroscopy applications that were designed and manufactured in-house. In 2008, he launched the SoloVPE® System that uses Slope Spectroscopy® that has become the standard for concentration measurement in the biotech industry. Craig leverages his background in business development and fiber optics in his current role at Repligen, where he focuses on Analytics. He holds a Bachelor’s degree in Economics from the University of Rochester.
Senior Vice President, Filtration
Tony MacDonald joined Repligen in June 2017, through the acquisition of Spectrum, Inc. where he served as President beginning in 2004. Previously, he worked at Pall Corporation as the Vice President of Sales and Marketing for the Life Science TFF products division until 2000. After Pall, Mr. MacDonald was the Vice President of Sales and Marketing for SolmeteX, where he refocused the company from an R&D company into a commercial success. He brings many years of experience in the sale and marketing of filtration and separations products.
Vice President, Business Operations
Maria Nieradka joined Repligen in September 2019 as Vice President of Business Operations to implement programs and processes to build leading edge capability across Business Units, R&D and Operations. Prior to joining Repligen, Maria held leadership roles of Senior Vice President and Vice President in multiple Fortune 500 Pharmaceutical and Bio Tech companies, including Bristol-Myers Squibb, Johnson and Johnson, Merck and Biogen. Over the past 35 years, Maria successfully launched over 30 new products, led merger and acquisition activities for 5 large mergers and implemented 4 Enterprise Resource Planning systems. Most recently, Maria was SVP of Business Development Integration and SVP of Global Supply Chain for Biogen from 2013 to 2019, where she led transformational programs and built capability to enhance customer service and double the growth of the company. Maria sponsors Diversity and Inclusion initiatives and serves on the Advisory Board for AWESOME, a non-profit organization focused on achieving women’s excellence in supply chain operations, management and education and as a Board Member of Harvard Kennedy Women’s Leadership Board. She holds Bachelor’s Degrees in Industrial Engineering and English from Rutgers College of Engineering and Douglass College and an MBA in Pharmaceutical/Chemical Studies from Fairleigh Dickinson University.
Senior Vice President, Strategy and Business Development
Kola Otitoju joined Repligen in 2020 as Senior Vice President of Strategy and Business Development. He is responsible for leading the development and execution of the Repligen growth strategy including partnerships, licensing, investments and mergers and acquisitions. Mr. Otitoju brings a wealth of experience in strategic planning and execution having led multiple transactions in excess of $100BN through his tenures in Investment Banking M&A at Credit Suisse and Banc of America Securities (8 years), large publicly traded corporations including Baxter and GE Healthcare (6 years), and private equity-backed companies like Candela Medical with Apax Partners (3 years). He also brings a strong technical background having been an Electrical Engineer earlier in his career. Mr. Otitoju has Masters Degrees in Business Administration from Harvard Business School and Electrical Engineering from Cornell University, in addition to a Bachelor's Degree in Information Systems Engineering from Imperial College London.
Senior Vice President, General Counsel and Corporate Secretary
Squire Servance joined Repligen in November 2020 as Senior Vice President, General Counsel and Corporate Secretary where he oversees the legal, corporate secretary, compliance, and enterprise risk functions. Mr. Servance joined Repligen from Baxter International, Inc. where he served as Associate General Counsel, Global Pharmaceuticals. Prior to joining Baxter, Mr. Servance worked in a variety of settings including as Director, Sr. Legal Counsel at Dr. Reddy’s Laboratories, as an attorney with Morgan, Lewis & Bockius LLP and as a law clerk for Judge Jerome A. Holmes of the U.S. Court of Appeals for the Tenth Circuit. Mr. Servance received his J.D. from Duke University School of Law. He received his M.B.A. with a concentration in corporate finance and a Certificate in Health Sector Management from Duke University, Fuqua School of Business. He received his B.S., with honors, with a double major in biomedical engineering and cell biology and neuroscience from Rutgers University, School of Engineering.
Vice President, Operations - Europe
Gustav Silfversparre was named Vice President of Operations at Repligen in March 2013 and is managing Repligen manufacturing sites in Europe. Before coming to Repligen, Mr. Silfversparre was Operations Director at Novozymes Biopharma AB, which was acquired by Repligen in December 2011. Between 2008-2010, Mr. Silfversparre was Head of Biopharma Coordination, a global project and production coordination function for the biopharma area within Novozymes.From 2002 to 2008, Mr. Silfversparre was Head of the Development Department at Novozymes Biopharma AB. Mr. Silfversparre received a Tech. Lic. Biotechnology at Royal Institute of Technology and M.Sc. Chemical Engineering at the Faculty of Engineering, Lund University.
Vice President, Global Sales
A graduate from the University of Leeds, England, Stephen Tingley has been a recognized contributor to the bioprocessing industry for over 25 years. Having worked initially for GSK, Mr. Tingley then joined Millipore creating and sharing expertise in sterile and downstream processing. At Millipore, Mr. Tingley became a recognized early champion of the development and adoption of single use technologies. He has had experience commercializing several leading technologies, including massively parallel microbioreactors system for upstream process development, multi-column chromatography and, most recently, leading the disposable chromatography team at Repligen that developed the OPUS® pre-packed column line.
Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth, a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves as a member on the board of directors of Assertio Therapeutics, Inc. and Medicines360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board of Directors include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.
Nicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 25 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. Mr. Barthelemy currently serves on the board of directors of Fluidigm, 908 Devices and Biocare Medical. Mr. Barthelemy received an M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board of Directors include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.
Ms. Eglinton Manner has served as a director of Repligen since June 2020. She brings to the director role over 23 years of leadership experience across multiple disciplines. Ms. Eglinton Manner currently serves as Senior Vice President, Advanced Diagnostics at Quest Diagnostics, which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. In her role at Quest Diagnostics, Ms. Eglinton Manner is responsible for growing the company’s nearly $2 billion genetic and molecular diagnostics portfolio, through innovation in specialty genetic offerings and services, productivity programs, key strategic alliances, and acquisitions. In addition to joining the Repligen board, Ms. Eglinton Manner serves as board director for the not-for-profit Thrive Networks, focused on advancing women and transforming health in underserved communities. Ms. Eglinton Manner holds a Bachelor of Science degree in Mechanical Engineering from the University of Notre Dame. Ms. Eglinton Manner’s qualifications to sit on the Repligen’s Board of Directors include her track record of delivering business expansion and profitability for rapidly growing global businesses, including her experience with integrating acquisitions and building operations excellence, with a commitment to quality and process improvements.
Tony J. Hunt was named our President and Chief Executive Officer and has served on our Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in
Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to our Board of Directors his deep understanding of the bioprocessing market.
Rohin Mhatre, Ph.D. was appointed to the Board in March 2020. Dr. Mhatre brings over 25 years of relevant experience to the director role, including his current position since January 2017, as Senior Vice President of Pharmaceutical Development, Engineering and Technology at Biogen. He has held numerous other roles of increasing responsibility within Biogen, which he joined in 1996, including six years as Vice President of Biopharmaceutical Development, where he led a 300-member team responsible for cell line, cell culture, purification and device development. Earlier in Dr. Mhatre’s career at Biogen, he focused on building out analytical development and technical services. Prior to Biogen, Dr. Mhatre led the purification and applications group at Applied BioSystems (formerly Perspective Biosystems). Dr. Mhatre holds a Ph.D.in Chemistry from Northeastern University. Dr Mhatre’s qualifications to sit on the Company’s Board of Directors include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows.
Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc., a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venturebacked single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir serves on the board of directors of the medical technology company Neuronetics, Inc. and life science company G1 Therapeutics, Inc. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S from Bentley University and an M.B.A. from Harvard University. Mr. Muir’s qualifications to sit on Repligen’s Board of Directors include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.
Thomas F. Ryan Jr. has served as a director of Repligen since September 2003. Mr. Ryan is currently an investor in various private companies. Mr. Ryan served as the President and Chief Operating Officer of the American Stock Exchange from October 1995 to April 1999. Prior to 1995, he held a variety of positions at the investment banking firm of Kidder, Peabody & Co., Inc., serving as the firm’s Chairman in 1995. He holds a B.A. from Boston College and is a graduate of the Boston Latin School. Mr. Ryan is a director for the New York State Independent System Operator and a director for BNY Mellon Asset Management Mutual Funds Board. Mr. Ryan’s qualifications to sit on the Company’s Board of Directors include his years of experience in the areas of securities trading and investment banking.
Richard D. Braatz is the Edwin R. Gilliland Professor at the Massachusetts Institute of Technology (MIT) where he does research in process data analytics, design, and control of advanced manufacturing systems. He received MS and Ph.D. from the California Institute of Technology and was the Millennium Chair and Professor at the University of Illinois at Urbana-Champaign and a Visiting Scholar at Harvard University before moving to MIT. He has consulted and/or collaborated with more than 30 companies including Merck, Novartis, Pfizer, Amgen, Biogen, and Bristol-Myers Squibb. He is a member of the National Academy of Engineering.
Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering, Emeritus in the Department of Chemical Engineering at MIT and founding Faculty Director, Emeritus of the Deshpande Center for Technological Innovation at MIT. With a BS in chemical engineering from the University of Pennsylvania and an SM and Ph.D. in Biochemical engineering from MIT, he has spent his professional career on the MIT faculty. He is an expert in process design, upstream and downstream bioprocess development, and manufacturing of pharmaceutical and biological products. Prof. Cooney has served as a consultant to or board member of multiple biotech and pharmaceutical companies and is chairman of Repligen’s Scientific Advisory Board.
Dr. Cramer is the William Weightman Walker Professor at Rensselaer Polytechnic Institute and is known for his contributions to the separation of complex biological products and the development of chromatographic materials, processes and predictive tools for enabling their biomanufacturing. In addition, he has made seminal contributions to the molecular understanding of the interactions that create unique selectivities in these separation systems. His lab is currently conducting research on several areas related to protein-surface interactions including prediction of protein binding affinity and multiscale modeling of chromatographic systems, development of efficient antibody and bispecific antibody separation systems, fundamental studies in multimodal chromatography, multilevel automated peptide synthesis/screening system for design of affinity peptides, smart biopolymer affinity precipitation systems, biophysics of protein interactions with surfaces, ligands and proteins, platformable strategies for effective removal of process HCPs and integrated semi-continuous biomanufacturing processes. He was the editor of Separation Science and Technology for 20 years and has been awarded the Alan S. Michaels Award for the Recovery of Biological Products (ACS Division of Biochemical Technology) and the ACS National Award in Separation Science and Technology. He was also awarded Rensselaer’s Distinguished Faculty Award as well as the School of Engineering Outstanding Professor and Research Excellence Awards. Dr. Cramer has been elected a fellow of the American Association for the Advancement of Science, American Institute of Chemical Engineers, the American Chemical Society and the American Institute for Medical and Biological Engineering.
Alfred Goldberg is a Professor of Cell Biology at Harvard Medical School. His research has concerned the mechanisms and regulation of protein breakdown in cells. His laboratory first demonstrated the existence of the non-lysosomal pathway for protein breakdown (now termed the ubiquitin-proteasome pathway), the 26S proteasome, and the ATP-dependent proteases responsible for protein degradation in bacteria. He also initiated the development of the proteasome inhibitor, Bortezomib/Velcade, now used worldwide for the treatment of multiple myeloma. His research accomplishments have been recognized with many honors, including three honorary degrees, the Gordon Alpert Prize, the Ernst Beutler Prize, and the 2021 Passano Award for Medical Research. He has been elected to the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts & Sciences, and he is among the 0.01% most cited authors in the life sciences. Dr. Goldberg has served frequently as a consultant to biotech companies and for 7 years served on the Board of Directors of Repligen.
Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.
J. Christopher Love is the Raymond A. (1921) and Helen E. St. Laurent Professor of Chemical Engineering and member of the Koch Institute for Integrative Cancer Research at MIT. In addition, he is an associate member at the Eli and Edythe L. Broad Institute, and at the Ragon Institute of MGH, MIT, and Harvard. Prof. Love received his Ph.D. in 2004 in physical chemistry at Harvard University. He extended his research into immunology at Harvard Medical School from 2004-2005, and at the Immune Disease Institute from 2005-2007. His research centers on using simple microsystems to monitor cells from clinical samples in chronic human diseases, and on developing new approaches to manufacturing biologic drugs and vaccines efficiently and affordably. Prof. Love was named a Dana Scholar for Human Immunology and a Keck Distinguished Young Scholar in Medical Research in 2009, one of Popular Science’s Brilliant 10 in 2010, and also a Camille Dreyfus Teacher-Scholar. At MIT, he is the Director of the Alternative Host Consortium, a unique MIT-Industry partnership advancing new manufacturing hosts for biopharmaceuticals and vaccines. He previously served as a Distinguished Engineer in Residence at Biogen (2015-2016), and also consults for several biotechnology and biopharmaceutical companies, including three current start-ups based on technologies from his lab at MIT (Honeycomb, OneCyte, and Sunflower).